ArticleExperimental hematology & oncology2022

IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity.

Kangkang Lv et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.